Clinical trial readout dates for Axsome Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 3 Solriamfetol 150 mg Excessive Sleepiness; Shift-work Disorder · NCT06568367 | December 2026 Recruiting |
| Phase 3 Solriamfetol 150 mg Binge-Eating Disorder · NCT06413433 | December 2026 Recruiting |
| Phase 3 AXS-05 (dextromethorphan-bupropion) Smoking Cessation · NCT07766655 | December 2027 Recruiting |
| Phase 3 Solriamfetol Binge-Eating Disorder · NCT06878976 | December 2027 Enrolling |
| Phase 3 Solriamfetol ADHD · NCT07773883 | December 2027 Enrolling |
| Phase 3 AXS-14 (Esreboxetine) Fibromyalgia · NCT07398417 | March 2028 Recruiting |
| Phase 3 AXS-14 (esreboxetine) Fibromyalgia · NCT07637162 | May 2028 Enrolling |
| Phase 3 Solriamfetol Dose A ADHD · NCT07717892 | June 2028 Recruiting |
Axsome Therapeutics Inc. reported $314M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $13M; at that rate the cash would last about 24 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Other Events — often topline trial data | 2026-11-02 |